Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 52 points (0.3%) at 15,523 as of Thursday, Aug. 8, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,945 issues advancing vs. 956 declining with 122 unchanged. The Health Care sector currently sits down 0.7% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the sector include Amgen ( AMGN), down 1.3%, and Pfizer ( PFE), down 0.6%. Top gainers within the sector include DexCom ( DXCM), up 23.7%, ResMed ( RMD), up 3.4%, Valeant Pharmaceuticals International ( VRX), up 2.7%, HCA Holdings ( HCA), up 1.7% and Boston Scientific ( BSX), up 1.6%. TheStreet would like to highlight 4 stocks pushing the sector lower today: 4. BioScrip ( BIOS) is one of the companies pushing the Health Care sector lower today. As of noon trading, BioScrip is down $2.48 (-14.9%) to $14.15 on heavy volume. Thus far, 1.8 million shares of BioScrip exchanged hands as compared to its average daily volume of 582,200 shares. The stock has ranged in price between $14.05-$15.13 after having opened the day at $15.00 as compared to the previous trading day's close of $16.63. BioScrip, Inc. provides home infusion and other home care services, and pharmacy benefit management (PBM) services in the United States. It operates in three segments: Infusion Services, Home Health Services, and PBM Services. BioScrip has a market cap of $1.1 billion and is part of the drugs industry. Shares are up 51.0% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate BioScrip a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates BioScrip as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, disappointing return on equity and poor profit margins. Get the full BioScrip Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.